Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2683678 | 0.82 | RAB9A (0.37) | MAPTALDH1A1NPSR1HSD17B10MEN1 | |
| SCHEMBL2344278 | 0.80 | NPC1 (0.41) | ALDH1A1MEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL2684431 | 0.79 | TSHR (0.36) | ALDH1A1NPSR1HSD17B10HPGDGAA | |
| SCHEMBL5281026 | 0.79 | TSHR (0.36) | ALDH1A1NPSR1HSD17B10HPGDGAA | |
| SCHEMBL5280813 | 0.71 | KDM4E (0.39) | MAPTALDH1A1HSD17B10HPGDGAA | |
| SCHEMBL2682948 | 0.71 | KDM4E (0.39) | MAPTALDH1A1HSD17B10HPGDGAA | |
| SCHEMBL2682454 | 0.71 | GLA (0.41) | ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL5399837 | 0.71 | GLA (0.41) | ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL2683507 | 0.70 | LMNA (0.40) | ALDH1A1KMT2ATSHR | |
| SCHEMBL2683687 | 0.70 | CTSG (0.37) | ALDH1A1MEN1KMT2ATSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115859-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | HEROLD PETER (CH) | 2012-05-10 | — | — | US | disclosed |
| US-20090270380-A1 | 3,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2009-10-29 | — | — | US | disclosed |
| EP-1863763-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| EP-1816122-A2 | 3,4,5-substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| WO-2006103275-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | CTSD, CTSL, CTSZ | MAPT 529/4885ALDH1A1 3787/4885NPSR1 617/4885 |
| US-20120115859-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | REN, AGTR1, AGTR2 | MAPT 4584/4885ALDH1A1 2345/4885NPSR1 161/4885 |
| US-20090270380-A1 | 3,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGTR1, AGTR2 | MAPT 4519/4885ALDH1A1 2391/4885NPSR1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.